Evaluation of Pharmacist-led Medication Reconciliation Service Benefits in Hospitalised Medical Patients

Impact of Routine Pharmacist-led Medication Reconciliation on Medication Discrepancies and Post-hospital Healthcare Utilisation

Background:

Transitions of care often lead to medication errors and unnecessary healthcare utilisation. It has been repeatedly shown that medication reconciliation can at least partially reduce this risk.

Objective:

The aim of this prospective pragmatic trial was to evaluate the effectiveness of pharmacist-led medication reconciliation offered to medical patients as part of routine clinical practise.

The main questions to be answered were:

  • the effectiveness of pharmacist-led medication reconciliation on medication discrepancies at discharge and 30 days after discharge
  • the effectiveness of pharmacist-led medication reconciliation on healthcare utilisation within 30 days after discharge.

Participants in the intervention group were offered the following:

  • medication reconciliation on admission
  • medication reconciliation on discharge, coupled with patient counselling, provided by clinical pharmacists.

Participants in the control group were offered standard care.

Study Overview

Status

Terminated

Detailed Description

Design: pragmatic, prospective, controlled clinical trial

Setting: Five general medical wards at the University Clinic of Respiratory and Allergic Diseases in Slovenia:

  • one intervention ward with a routine pharmacist-led medication reconciliation service
  • four control wards

Data collection:

  • Data collection and outcome assessment were performed by research pharmacists who were clinical pharmacists or final year clinical pharmacy residents not involved in the treatment of the included patients.
  • Data for the assessment of medication errors at discharge were obtained from the patients' medical records and the study documentation.
  • The reason for the patient's hospitalisation was obtained from the discharge letter and divided into acute or planned admissions. The main diagnosis was the reason for admission, while all other patient diagnoses listed were used to assess comorbidity.
  • Patient comorbidity was assessed using the Charlson Comorbidity Index
  • For patients in the control group the BPMH was collected in the same way as in the intervention group. However, it was only used for study purposes and was not documented in the patients' medical records
  • Data on healthcare utilisation and medication discrepancies after hospital discharge were collected through patients or caregivers' phone interview.

Study Type

Interventional

Enrollment (Actual)

553

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Select State
      • Golnik, Select State, Slovenia, 4202
        • University Clinic of Respiratory and Allergic Diseases Golnik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • All adult medical patients admitted to the study wards

Exclusion Criteria:

  • patients who do not speak Slovenian,
  • transferred from another ward,
  • previously included in the same study.

Subsequent exclusion from the analysis:

  • patients hospitalised only for diagnostic purposes,
  • patients transferred to another ward or hospital,
  • patients that died during hospitalisation,
  • patients from the control group who were offered medication reconciliation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intervention Group
Patients were offered pharmacist- led medication reconciliation on admission and discharge coupled with patient counselling.
The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
No Intervention: Control Group
Patients received standard care - only written instructions on discharge medications in the discharge letter, according to the standard practice.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Unplanned healthcare utilisation within 30 days after discharge
Time Frame: within 30 (±5) days after hospital discharge
Unplanned healthcare utilisation within 30 days of hospital discharge was defined as any unplanned visit to a general practitioner, specialist, emergency department (ED), or hospitalisation or death. The visits were classified as unplanned, if sudden health problems required medical attention, and planned, if scheduled. Data on mortality due to any reason were also collected 30 days after discharge. For each patient, only the most detrimental outcome was classified.
within 30 (±5) days after hospital discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serious unplanned healthcare utilisation within 30 days after discharge
Time Frame: within 30 (±5) days after hospital discharge
Serious unplanned healthcare utilisation were defined as any unplanned ED visit or hospitalisation or death within 30 days from hospital discharge.
within 30 (±5) days after hospital discharge
Clinically important medication errors at discharge
Time Frame: On the day of hospital discharge (up to 365 days from hospital admission)
Unintentional discrepancies and undocumented intentional discrepancies between the therapy the patient was taking before admission (BMPH) and the therapy recommended in the discharge letter were defined as medication errors. Their clinical importance was assessed using a 4-point Likert scale ranging from not important, not very important, very important to life-threatening medication errors. Very important and life-threatening medication errors represent clinically important medication errors.
On the day of hospital discharge (up to 365 days from hospital admission)
Medication discrepancies at 30 days
Time Frame: At 30 (±5) days after hospital discharge

Medication discrepancies 30 (±5) days after hospital discharge were defined as the discrepancies between the discharge therapy and the therapy the patient was taking 30 (±5) days after hospital discharge.

The discrepancies were defined as intentional if the patient intentionally took the therapy differently than recommended in the discharge letter. The reason for the discrepancy was also recorded - the patient's own informed decision or due to instructions from the treating physician (general practitioner, specialist).

Unintentional discrepancies were defined as discrepancies from the therapy recommended in the discharge letter of which the patients were unaware. The clinical importance of unintentional discrepancies was assessed using a 4-point Likert scale, ranging from not important, not very important, very important, to life- threatening.

At 30 (±5) days after hospital discharge
All healthcare utilisation within 30 days after discharge
Time Frame: within 30 (±5) days after hospital discharge
Healthcare visits within 30 days of hospital discharge were defined as any visit to a general practitioner, specialist, emergency department (ED), or hospitalisation. These visits were classified as unplanned, if sudden health problems required medical attention, and planned, if scheduled. Data on mortality due to any reason were also collected 30 days after discharge. For each patient, only the most detrimental outcome was classified.
within 30 (±5) days after hospital discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2019

Primary Completion (Actual)

October 18, 2020

Study Completion (Actual)

December 31, 2020

Study Registration Dates

First Submitted

December 22, 2023

First Submitted That Met QC Criteria

January 12, 2024

First Posted (Estimated)

January 17, 2024

Study Record Updates

Last Update Posted (Estimated)

January 17, 2024

Last Update Submitted That Met QC Criteria

January 12, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Medication Reconciliation

Clinical Trials on Pharmacist-led Medication Reconciliation

3
Subscribe